Trial Search Results
Diffusion Weighted Imaging Evaluation for Understanding Stroke Evolution Study-2 (DEFUSE-2)
Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution Study 2 (DEFUSE 2) is a multi-center pilot study to determine if cerebral perfusion imaging can help identify which patients, who are ineligible for intravenous tissue plasminogen activator (iv tPA) therapy or have failed iv tPA therapy, are most likely to benefit from an endovascular clot removal procedure.
Stanford is currently not accepting patients for this trial.
Collaborator: National Institute of Neurological Disorders and Stroke (NINDS)
1. Age 18 years and older
2. Clinical diagnosis of ischemic stroke and a score of 5 or more points in the NIHSS.
3. Planned to undergo intra-arterial (IA) therapy for acute hemispheric stroke (Either as
primary therapy or as adjuvant therapy following intravenous tPA treatment)
4. Planned to have a standard MRI including perfusion imaging and MR angiography of the
circle of Willis (MRA) prior to IA therapy
5. Intra-arterial thrombectomy can be started within 90 minutes of completion of MRI scan
and within 12 hours of symptom onset. (Start of IA therapy is defined as the time of
insertion of the femoral artery sheath; Time of brain scan is defined as the time that
the scan is completed)
6. Able to obtain informed consent (informed consent should be obtained prior to the
baseline MRI scan).
1. Any pre-existing neurological illness resulting in a modified Rankin Scale Score of 3
or higher prior to the qualifying stroke
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study